http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014108309-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-08 |
| filingDate | 2012-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014108309-A |
| titleOfInvention | ANTIPOLIUBIKVITIN ANTIBODIES AND METHODS OF APPLICATION |
| abstract | 1. An isolated antibody that specifically binds to a first polyubiquitin containing a C-terminus bond to an N-terminus, said antibody not binding specifically to a second polyubiquitin containing a lysine bond. An isolated antibody that specifically binds to the first polyubiquitin containing a C-terminus bond to the N-terminus and to a second polyubiquitin containing a lysine bond, and this antibody does not bind specifically to monoubiquitin, and the antibody binds to the second polyubiquitin with significantly lower affinity binding compared to the binding affinity of the antibody for the first polyubiquitin. 3. An isolated antibody that specifically binds to a polyubiquitin containing a C-terminal bond to the N-terminus, wherein said antibody does not specifically bind to monoubiquitin. 4. The antibody according to claim 3, containing at least one hypervariable sequence (HVR) selected from HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2 and HVR-H3 any of SEQ ID NO: 1, 4, 19 and 50-57; SEQ ID NO: 2 and 58-63; SEQ ID NO: 3, 5, 6, 20, 21, and 64-72; SEQ ID NO: 7, 10, 13, 16, 22 and 73-81; SEQ ID NO: 8, 11, 14, 17, 23, 24, and 82-86; and SEQ ID NO: 9, 12, 15, 18, and 87-93, respectively. 5. The antibody according to claim 3, containing at least one sequence selected from HVR-L1, HVR-L2 and HVR-L3, wherein HVR-L1 contains the amino acid sequence RASQXVXXXVA (SEQ ID NO: 39), where amino acid X is selected from amino acids D, S and G, the amino acid is selected from S and D, the amino acid is selected from S, T and N, and the amino acid is selected from A and S; wherein HVR-L2 contains the amino acid sequence of SEQ ID NO: 2; and wherein HVR-L3 contains the amino acid sequence QQXXXXXPXT (SEQ ID NO: 40), where the amino acid is selected from S, Y and H, the amino acid is selected from Y and F, the amino acid is selected from T, Y � |
| priorityDate | 2011-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 55.